Nasdaq · Healthcare

Caris Life Sciences, Inc. (CAI)

As-reported financials and recent SEC filings for Caris Life Sciences, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$812.0M

Net income

$-68.1M

Net margin

-8.4%

Diluted EPS

$-3.22

ROE

-11.8%

P/E (TTM)

—

Market cap

$5.23B

Debt / equity

0.7×

Income statement (as reported)

Line	FY2025	FY2025	FY2025
Revenue	$812.0M	$412.3M	$306.1M
Gross profit	—	—	—
Operating income	$45.1M	$-257.1M	$-319.6M
Net income	$-68.1M	$-281.9M	$-341.4M
Diluted EPS	$-3.22	$-2.13	$-2.65

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

8-A12B2026-06-16

CERT2026-06-16

8-K2026-06-05

42026-06-02

42026-06-02

42026-05-18

42026-05-18

42026-05-18

Go deeper on CAI

Search Caris Life Sciences, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.